Compare Stocks: TLSA, PROK, AUTL, and BNTC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$1.24 -6.4%	$1.74	$1.12 ▼ $2.58	$351.33M	2.32	2.54 million shs	3.84 million shs
BNTC Benitec Biopharma	$9.47 +2.0%	$9.82	$7.89 ▼ $14.39	$323.77M	0.26	195,139 shs	120,637 shs
PROK ProKidney	$1.13 +1.8%	$1.56	$0.87 ▼ $2.88	$335.58M	1.9	1.48 million shs	595,556 shs
TLSA Tiziana Life Sciences	$0.62 +1.8%	$0.94	$0.57 ▼ $1.90	$77.65M	0.49	556,162 shs	359,630 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	0.00%	-6.71%	-27.07%	-37.74%	0.00%
BNTC Benitec Biopharma	-5.98%	+10.48%	+4.62%	-24.80%	-28.01%
PROK ProKidney	-3.48%	+3.74%	-36.21%	-25.00%	-58.89%
TLSA Tiziana Life Sciences	-8.80%	-11.58%	-48.72%	-38.36%	-65.13%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$1.24 -6.4%	$1.74	$1.12 ▼ $2.58	$351.33M	2.32	2.54 million shs	3.84 million shs
BNTC Benitec Biopharma	$9.47 +2.0%	$9.82	$7.89 ▼ $14.39	$323.77M	0.26	195,139 shs	120,637 shs
PROK ProKidney	$1.13 +1.8%	$1.56	$0.87 ▼ $2.88	$335.58M	1.9	1.48 million shs	595,556 shs
TLSA Tiziana Life Sciences	$0.62 +1.8%	$0.94	$0.57 ▼ $1.90	$77.65M	0.49	556,162 shs	359,630 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	0.00%	-6.71%	-27.07%	-37.74%	0.00%
BNTC Benitec Biopharma	-5.98%	+10.48%	+4.62%	-24.80%	-28.01%
PROK ProKidney	-3.48%	+3.74%	-36.21%	-25.00%	-58.89%
TLSA Tiziana Life Sciences	-8.80%	-11.58%	-48.72%	-38.36%	-65.13%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	2.88	Moderate Buy	$10.00	696.81% Upside
BNTC Benitec Biopharma	2.60	Moderate Buy	$22.00	135.29% Upside
PROK ProKidney	2.75	Moderate Buy	$10.00	773.36% Upside
TLSA Tiziana Life Sciences	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest TLSA, PROK, AUTL, and BNTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/11/2026	AUTL Autolus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
11/11/2026	AUTL Autolus Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
11/3/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
11/2/2026	BNTC Benitec Biopharma	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
11/2/2026	AUTL Autolus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy
10/28/2026	PROK ProKidney	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$8.00
10/23/2026	BNTC Benitec Biopharma	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$14.00
10/19/2026	TLSA Tiziana Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/15/2026	BNTC Benitec Biopharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/6/2026	PROK ProKidney	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/6/2026	BNTC Benitec Biopharma	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform

(Data available from 11/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$117.39M	2.85	N/A	N/A	$0.67 per share	1.87
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	$5.15 per share	N/A
PROK ProKidney	$890K	388.94	N/A	N/A	($3.36) per share	-0.34
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$287.53M	-$1.06	N/A	N/A	N/A	-238.66%	-178.66%	-49.34%	N/A
BNTC Benitec Biopharma	-$45.55M	-$0.98	N/A	N/A	N/A	N/A	-28.41%	-27.76%	11/13/2026 (Estimated)
PROK ProKidney	-$68.99M	-$0.55	N/A	N/A	N/A	-10,288.39%	N/A	-27.39%	N/A
TLSA Tiziana Life Sciences	-$18.43M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest TLSA, PROK, AUTL, and BNTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	Q1 2027	BNTC Benitec Biopharma	-$0.2686	N/A	N/A	N/A	N/A	N/A
11/10/2026	Q3 2026	AUTL Autolus Therapeutics	-$0.21	-$0.21	N/A	-$0.21	$39.54 million	$41.24 million
9/14/2026	Q4 2026	BNTC Benitec Biopharma	-$0.2643	-$0.26	+$0.0043	-$0.2590	$13.70 million	N/A
8/11/2026	Q2 2026	AUTL Autolus Therapeutics	-$0.21	-$0.15	+$0.06	-$0.15	$38.56 million	$45.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	1.04	4.89	4.40
BNTC Benitec Biopharma	N/A	34.00	34.00
PROK ProKidney	N/A	8.36	8.36
TLSA Tiziana Life Sciences	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
BNTC Benitec Biopharma	52.19%
PROK ProKidney	51.59%
TLSA Tiziana Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
BNTC Benitec Biopharma	7.96%
PROK ProKidney	39.83%
TLSA Tiziana Life Sciences	39.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	752	266.16 million	197.76 million	Optionable
BNTC Benitec Biopharma	24	34.89 million	32.11 million	Optionable
PROK ProKidney	231	302.32 million	181.91 million	Optionable
TLSA Tiziana Life Sciences	10	127.26 million	76.58 million	Optionable

TLSA, PROK, AUTL, and BNTC Headlines

Recent News About These Companies

BTIG Sticks to Their Buy Rating for Tiziana Life Sciences (TLSA)

1 hour ago | theglobeandmail.com

Tiziana Life Sciences Ltd (TLSA) Discusses Positive Phase 2a INFORM-MS Results for Intranasal Foralumab in Nonactive Secondary Progressive Multiple Sclerosis Transcript

November 9 at 8:00 PM | seekingalpha.com

Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients ...

November 9 at 5:18 PM | markets.businessinsider.com

Tiziana’s nasal foralumab reduces microglial activation in progressive MS trial

November 9 at 5:18 PM | finance.yahoo.com

Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intranasal Foralumab

November 9 at 1:30 PM | globenewswire.com

Tiziana Life Sciences to Present at BIO-Europe 2026 and Host KOL Webcast

November 9 at 12:17 PM | finance.yahoo.com

Tiziana Life Sciences to advance foralumab partnering talks at BIO-Europe 2026

November 9 at 12:17 PM | finance.yahoo.com

Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results

November 5, 2026 | globenewswire.com

Tiziana's Intranasal Foralumab Meets Primary Endpoints In Phase 2a Multiple Sclerosis Trial

November 3, 2026 | rttnews.com

Tiziana Eyes Next Foralumab Milestones After Positive Progressive MS Data; Stock Down

November 2, 2026 | rttnews.com

Tiziana Reports Positive Imaging And Fatigue Data For Foralumab

November 2, 2026 | rttnews.com

Tiziana Life Sciences reports positive phase 2a results for Intranasal Foralumab in MS

November 2, 2026 | finance.yahoo.com

Tiziana says nasal MS drug cuts brain inflammation in mid-stage study

November 2, 2026 | yahoo.com

Tiziana's experimental MS treatment meets main goals in mid-stage study

November 2, 2026 | reuters.com

Tiziana Life Sciences (NASDAQ:TLSA) Stock Rating Raised to Sell at Wall Street Zen

October 24, 2026 | marketbeat.com

Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto

October 21, 2026 | markets.businessinsider.com

Tiziana Life Sciences Ltd Reports Earnings Results for the Half Year Ended June 30, 2026

October 17, 2026 | marketscreener.comM

Tiziana Life Sciences Doses Last Patient in Phase 2 Trial of Intranasal Foralumab in Alzheimer's Disease

October 16, 2026 | finance.yahoo.com

Tiziana Completes Enrollment And Dosing In Phase 2 Alzheimer's Study Of Intranasal Foralumab

October 16, 2026 | rttnews.com

Tiziana completes dosing in Phase 2 Alzheimer’s trial of intranasal foralumab

October 16, 2026 | finance.yahoo.com

Tiziana Life Sciences, Ltd. Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer?S Disease

October 16, 2026 | marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA, PROK, AUTL, and BNTC Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$1.24 -0.09 (-6.44%)

Closing price 04:00 PM Eastern

Extended Trading

$1.26 +0.02 (+1.94%)

As of 07:58 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Benitec Biopharma NASDAQ:BNTC

$9.47 +0.19 (+2.05%)

Closing price 04:00 PM Eastern

Extended Trading

$9.47 0.00 (0.00%)

As of 07:56 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

ProKidney NASDAQ:PROK

$1.13 +0.02 (+1.80%)

Closing price 04:00 PM Eastern

Extended Trading

$1.13 +0.00 (+0.18%)

As of 07:50 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Tiziana Life Sciences NASDAQ:TLSA

$0.62 +0.01 (+1.77%)

Closing price 04:00 PM Eastern

Extended Trading

$0.62 +0.00 (+0.32%)

As of 07:55 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TLSA, PROK, AUTL, and BNTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TLSA, PROK, AUTL, and BNTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TLSA, PROK, AUTL, and BNTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA, PROK, AUTL, and BNTC Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

Benitec Biopharma NASDAQ:BNTC

ProKidney NASDAQ:PROK

Tiziana Life Sciences NASDAQ:TLSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TLSA, PROK, AUTL, and BNTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TLSA, PROK, AUTL, and BNTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TLSA, PROK, AUTL, and BNTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA, PROK, AUTL, and BNTC Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

Benitec Biopharma NASDAQ:BNTC

ProKidney NASDAQ:PROK

Tiziana Life Sciences NASDAQ:TLSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools